APC and hepatocellular carcinoma: Its aberrant activation through mutations in key regulators—including adenomatous polyposis coli (APC), axis inhibition protein (AXIN), and CTNNB1—drives HCC progression, therapy resistance, and disease recurrence (78, 380–383).